CDK-IN-14
CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Caspase; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk-in-14-1.html
Smiles
COC1=C(OC)C=C(N=C(NC2=CC=C(OCC3=CC(F)=CC=C3)C(Cl)=C2)N=C4NCC5=CC=CC=C5)C4=C1
Molecular Formula
C30H26ClFN4O3
Molecular Weight
545.00
References & Citations
[1]Venkatesan G, et al. Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs[J]. Bioorganic Chemistry, 2024: 107777.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2067018-01 0.1 mL
HRP-Linked Polyclonal Antibody to Vanin 1 (VNN1)
Sign In for Pricing
View Details MBS2067018-02 0.2 mL
HRP-Linked Polyclonal Antibody to Vanin 1 (VNN1)
Sign In for Pricing
View Details